logo-loader
RNS
Vulcan Two Group plc

Company Name Change Effective – Molecule Group plc

RNS Number : 5013X
Molecule Group PLC
05 October 2026
 

 

5 October 2026

Molecule Group plc

(the “Company”, "Group" or "Molecule")

 

Company Name Change Effective – Molecule Group plc

 

Vulcan Two Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, confirms the change of its name to Molecule Group plc.

 

Companies House issued a change of name certificate on 2 October 2026 and the name change to Molecule Group plc has become effective immediately. The Company confirms that the change of name has been notified to the London Stock Exchange and trading in the Company's shares under the new company name and new TIDM code/ticker symbol ‘MOL’ will commence today at 8.00 a.m.

 

Molecule - One Group, One Brand:

 

  •  

Company name change to Molecule Group plc reflects the Group’s progress into an integrated ePharmacy platform.

 

  •  

Molecule brand creates a single identity across the Group’s consumer, veterinary and professional healthcare channels.

 

  •  

New B2C website molecule.co.uk, brings together a new Molecule clinic, an enhanced over-the-counter range and our veterinary offering in a single portal. This gives the direct-to-consumer business a single modern platform, a wider basket per customer and one place in which to invest in customer acquisition and retention.

 

  •  

New investor relations website will be: investors.molecule.co.uk

 

Michael Kraftman, Chief Executive Officer of Molecule, commented: “We are delighted to launch the Molecule brand which marks an important milestone in the Group's development and provides a single identity across the Group’s consumer, veterinary and professional channels in place of a collection of acquired names, and a common focus for marketing investment.”

 

The Company's ISIN and SEDOL will remain unchanged.

 

Shareholders are unaffected by the change of name and existing share certificates should be retained and will remain valid.

 

For further information please contact:

 

Molecule Group plc

Michael Kraftman, Chief Executive Officer

Keith Butcher, Chief Finance Officer

Brendan O’Brien, Chief Operating Officer

investors.molecule.co.uk

Email: corporate@molecule.co.uk

Canaccord Genuity Limited
(Nominated Adviser and Sole Broker)

Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000
 

Alma Strategic Communications
(Financial PR)

Justine James / Sam Modlin / Will Merison

Email: molecule@almastrategic.com

Tel: +44 (0) 20 3405 0205

 

Notes to Editors

Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CANUPGMCUUPQURC
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read